These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 36960580)

  • 1. Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.
    Stangl-Kremser J; Ricaurte-Fajardo A; Subramanian K; Osborne JR; Sun M; Tagawa ST; Bander NH
    Prostate; 2023 Jul; 83(10):901-911. PubMed ID: 36960580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving role of
    Satapathy S; Sood A; Das CK; Mittal BR
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):880-890. PubMed ID: 33746213
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Ballal S; Yadav MP; Sahoo RK; Tripathi M; Dwivedi SN; Bal C
    Prostate; 2021 Jun; 81(9):580-591. PubMed ID: 33905559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Satapathy S; Sahoo RK; Bal C
    J Nucl Med; 2023 Aug; 64(8):1266-1271. PubMed ID: 37169534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.
    Stangl-Kremser J; Sun M; Ho B; Thomas J; Nauseef JT; Osborne JR; Molina A; Sternberg CN; Nanus DM; Bander NH; Tagawa S
    Prostate; 2023 Oct; 83(14):1351-1357. PubMed ID: 37424145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
    Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer.
    Sun M; Niaz MJ; Niaz MO; Tagawa ST
    Curr Oncol Rep; 2021 Mar; 23(5):59. PubMed ID: 33778927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First Clinical Results for PSMA-Targeted α-Therapy Using
    Zacherl MJ; Gildehaus FJ; Mittlmeier L; Böning G; Gosewisch A; Wenter V; Unterrainer M; Schmidt-Hegemann N; Belka C; Kretschmer A; Casuscelli J; Stief CG; Unterrainer M; Bartenstein P; Todica A; Ilhan H
    J Nucl Med; 2021 May; 62(5):669-674. PubMed ID: 33008928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
    Sathekge MM; Lawal IO; Bal C; Bruchertseifer F; Ballal S; Cardaci G; Davis C; Eiber M; Hekimsoy T; Knoesen O; Kratochwil C; Lenzo NP; Mahapane J; Maserumule LC; Mdlophane AH; Mokoala KMG; Ndlovu H; Pant V; Rathke H; Reed J; Sen IB; Singh A; Sood A; Tauber R; Thakral P; Yadav MP; Morgenstern A
    Lancet Oncol; 2024 Feb; 25(2):175-183. PubMed ID: 38218192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
    Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
    Vlachostergios PJ; Niaz MJ; Skafida M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
    Prostate; 2021 Apr; 81(5):279-285. PubMed ID: 33465252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
    Satapathy S; Mittal BR; Sood A
    Clin Nucl Med; 2020 Dec; 45(12):935-942. PubMed ID: 32956129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis.
    Parida GK; Panda RA; Bishnoi K; Agrawal K
    Med Princ Pract; 2023; 32(3):178-191. PubMed ID: 37247612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mCRPC Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Mdlophane A; Maes A; Mokoala K; Mathabe K; Van C; Wiele D; Morgenstern A
    J Nucl Med; 2022 Oct; 63(10):1496-1502. PubMed ID: 35177427
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of
    Lee DY; Kim YI
    J Nucl Med; 2022 Jun; 63(6):840-846. PubMed ID: 34503960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival outcomes of salvage [
    Ballal S; Yadav MP; Satapathy S; Raju S; Tripathi M; Damle NA; Sahoo RK; Bal C
    Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3777-3789. PubMed ID: 37462775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with
    van der Doelen MJ; Mehra N; van Oort IM; Looijen-Salamon MG; Janssen MJR; Custers JAE; Slootbeek PHJ; Kroeze LI; Bruchertseifer F; Morgenstern A; Haberkorn U; Kratochwil C; Nagarajah J; Gerritsen WR
    Urol Oncol; 2021 Oct; 39(10):729.e7-729.e16. PubMed ID: 33353867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
    Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
    Yadav MP; Ballal S; Sahoo RK; Tripathi M; Damle NA; Shamim SA; Kumar R; Seth A; Bal C
    PLoS One; 2021; 16(5):e0251375. PubMed ID: 33970962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.